Humana Inc vs Okta, Inc. — how do they compare? Humana Inc trades at $444.74 (market cap $46.49B), while Okta, Inc. trades at $222.45 (market cap $38.50B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.91% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Okta, Inc. for 44 Days on average.
| HUM | OKTA | |
|---|---|---|
Market Cap | $46.49B | $38.50B |
Volume | 2,567,704 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $409.85 | $220.21 |
52-Week Low | $163.67 | $62.93 |
Typical Hold Time | 53 Days | 44 Days |
Enterprise Value | $53.84B | $36.25B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
OKTA trades at $218.00, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $2.61 billion in 2025 with a net income turnaround to $28 million. Recent earnings beats and positive analyst sentiment (73.58% buy ratings) highlight momentum, though high valuation ratios like a P/E of 131.33 pose concerns. Key developments include AI security initiatives unveiled at Oktane 2026, driving media attention.
Outlook: OKTA's focus on AI agent security and identity management positions it for growth in cybersecurity, but elevated valuations and insider selling require caution. Risks include competitive pressures and execution challenges. The consensus price target of $201.30 suggests modest downside, yet innovation catalysts offer long-term potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →